Biofourmis Selected by Vanderbilt University Medical Center for CAR T-Cell Therapy Study
Biofourmis has announced that Vanderbilt University Medical Center has selected Biofourmis to support a clinical study measuring the safety and efficacy of monitoring patients in a home-like outpatient setting after receiving a leading oncology drug.
Patients with large B-cell lymphoma will receive the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (YESCARTA®) by Kite, a Gilead Company. Instead of remaining in the hospital after receiving the immunotherapy, which is the current standard of care, patients will be discharged to a home-like setting near the medical center. In addition to periodic physical exams, several vital signs will be continuously monitored through Biofourmis’ analytics platform, which will assist the clinical team in detecting side effects of therapy to intervene as appropriate.
Read more about this announcement here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
